Teva Pharma stock rating reiterated at Buy by BofA on Austedo growth

BofA Securities has reiterated its Buy rating and $22.00 price target on Teva Pharmaceutical Industries (NYSE:TEVA), citing strong growth prospects for Austedo, which is projected to achieve a 10% revenue CAGR from 2024-2029 and significant market share in the VMAT2 inhibitor category. This positive outlook is echoed by other firms like Goldman Sachs, UBS, and Truist, who highlight Teva's "undemanding valuation," attractive new product cycle, and strategic financial goals including a 30% operating profit margin and over $2.7 billion in free cash flow by 2027. While potential Medicare IRA price negotiations for Austedo remain a key focus and source of short interest, analysts maintain a positive view on Teva's branded growth and operational execution.

Analysis

A strong bullish consensus is forming around Teva Pharmaceutical Industries (TEVA), with BofA Securities, Goldman Sachs, UBS, and Truist all issuing Buy ratings and price targets suggesting significant upside from its current level of $16.42. The core of this optimism is the growth trajectory of its key branded drug, Austedo, which BofA projects will achieve a ~10% revenue compound annual growth rate from 2024 to 2029 and capture a 50% market share in the VMAT2 inhibitor category. This growth is supported by physician survey data indicating an under-treated market and no new payer restrictions. While analysts view Teva's valuation as "undemanding," the primary risk tempering the outlook is the potential impact of Medicare IRA price negotiations on Austedo, which could result in a 20-25% net price reduction and is a key driver of current short interest. The company's strategic plan, aiming for a 30% operating profit margin and over $2.7 billion in free cash flow by 2027, alongside a robust biosimilars portfolio, is positioned to offset limited growth in its legacy generics segment and fund further R&D.

Key Decisions for Investors

• Given the strong analyst consensus and price targets ranging from $22.00 to $30.00, investors may consider the current valuation an attractive entry point, aligning with the view that the stock is undervalued.
• Investors must closely monitor developments related to the Medicare IRA price negotiations for Austedo, as a significant price reduction represents the primary headwind to the company's growth thesis.
• Focus on upcoming catalysts, including the Q2 earnings release (benchmarked against JPMorgan's $4.3B revenue and $0.63 EPS estimates) and the investor day, for updates on strategic execution and financial guidance.
• The performance of the branded portfolio, specifically Austedo's market share gains and Uzedy's uptake, should be tracked as the key driver for achieving the company's 2027 financial goals.